KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Travere Therapeutics (TVTX) over the last 12 years, with Q4 2024 value amounting to $3.5 million.

  • Travere Therapeutics' Treasury Shares rose 2238.02% to $3.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.5 million, marking a year-over-year increase of 2238.02%. This contributed to the annual value of $3.5 million for FY2024, which is 2238.02% up from last year.
  • Travere Therapeutics' Treasury Shares amounted to $3.2 million in Q4 2014, which was up 23585.02% from $3.2 million recorded in Q3 2014.
  • In the past 5 years, Travere Therapeutics' Treasury Shares registered a high of $3.5 million during Q4 2024, and its lowest value of $1.1 million during Q4 2020.
  • Over the past 5 years, Travere Therapeutics' median Treasury Shares value was $2.3 million (recorded in 2022), while the average stood at $2.3 million.
  • Over the last 5 years, Travere Therapeutics' Treasury Shares had its largest YoY gain of 23585.02% in 2014, and its largest YoY loss of 23585.02% in 2014.
  • Quarter analysis of 2 years shows Travere Therapeutics' Treasury Shares stood at $957272.0 in 2013, then surged by 235.85% to $3.2 million in 2014.
  • Its last three reported values are $3.5 million in Q4 2024, $2.9 million for Q4 2023, and $2.3 million during Q4 2022.